© 2023 Peel Therapeutics | All rights reserved |
Who we are
Peel Therapeutics is on an expedition to unlock nature’s secrets and overcome life-threatening conditions. These evolutionary outliers rarely make their way to patients, and we are determined to change that.
We are an evolutionary-inspired, clinical-stage biotech company developing medicines to transform patients’ lives. Peel (the Hebrew word for “elephant”) launched with our focus on cancer-fighting proteins in elephants and we quickly recognized the power of using evolution’s solutions to treat and prevent disease. In addition to developing elephant p53 (EP53) nanoparticles for the treatment of cancer, our team is advancing additional therapies derived from nature’s superabilities to treat cancer and inflammation.
Life science R&D has produced countless new therapies with positive health outcomes, but it cannot compare to ages of evolutionary history. We seek out distinct proteins and molecules in nature that have exceeded what we thought was biologically possible. We then apply our expertise and technology to rapidly translate this evolutionary biology and advance our therapeutic pipeline to treat a spectrum of devastating conditions, including cancer and inflammation. Our therapy’s efficacy is derived from its distinctive biological structure, which enables it to accumulate in disease-relevant cells and interfere only with disease processes— to maximize impact while minimizing side-effects.
“Peel” is the Hebrew word for elephant.
Elephants are naturally cancer-resistant creatures.
The Chinese Happy Tree has been used to treat many ailments including:
About 25% of the drugs prescribed worldwide are derived from plants.
Peel Therapeutics’ mission is to engineer evolutionary biology to improve patient lives.
Peel Therapeutics aims to develop safe and highly effective medicines that transform patient care.
Our multidisciplinary team across the US and Israel offers a unique blend of scientific and medical expertise, enthusiasm and curiosity. We hail from all corners of industry, academia, and clinical medicine, and the patients we serve are the driving force behind the work we do every day.
The potential of Peel’s pipeline fueled by the company’s evolutionary insight is enormous. Peel scientists have identified exciting therapeutic targets, have developed cutting-edge delivery technology, and have demonstrated strong preclinical success – with their first clinical trial now enrolling patients. Peel’s approach avoids the common missteps in pharma drug pipelines by taking advantage of “nature’s R&D pipeline” with hundreds of millions of years of evolutionary success. Their first three assets scratch the surface of the opportunities for Peel and I’m excited by the scale at which Peel can positively impact patient lives.”
I have been an enthusiastic investor in Peel Therapeutics since the beginning. Dr. Schiffman and his remarkable team have insight and talent that learns from the lessons of evolution, medicine and chemistry. They translate that knowledge into treatments and defenses for human weaknesses and disease. They also have a remarkable judgement about timelines of development that will optimize the return on investment into the Company.”
I am proud to be an investor and board member of Peel Therapeutics, a company I believe will have disproportionate impact in the realm of curing disease and restoring health. The Company is advancing new breakthroughs at the intersection of evolutionary science and technology to bring nature’s insights to new therapeutic treatments. Its visionary leadership from CEO and Co-Founder Dr. Joshua Schiffman and Co-Founder Avi Schroeder is leading multi-disciplinary teams in the US and Israel who are creative, rigorous and tenacious in advancing the work and the pathway to impact.”